XPH News and Press, SPDR S&P Pharmaceuticals From 01/30/24

Transaction highlights: To acquire Carlisle Interconnect Technologies for $2.0 billion in cash Adds leading capabilities in harsh environment interconnect solutions Broad product portfolio highly complementary to Amphenol’s existing interconnect solutions Accelerates lo...

Fourth Quarter 2023 Highlights: Record Sales of $3.33 billion, up 3% in U.S. dollars and down 1% organically compared to the fourth quarter of 2022 GAAP Diluted EPS of $0.83, up 1% compared to prior year Record Adjusted Diluted EPS of $0.82, up 5% compared to prior year ...

2024-01-17 11:38:06 ET More on Health Care Select Sector SPDR: XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech T...

2024-01-16 04:50:00 ET Summary Why US banks could be poised for a rebound? Sectors primed for a pivot if the Fed cuts. The outlook for healthcare and real estate. The potential for interest rate cuts this year by the U.S. Federal Reserve is raising the outlook for ...

2024-01-15 12:40:00 ET Summary All decisions around investing, everything we're seeing everyone doing is now colored by the rate situation. Artificial intelligence is a constantly growing and transforming phenomenon. Unlike artificial intelligence, a lot of the most exciting a...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...